Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker - Concepedia

Concepedia

Publication | Closed Access

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

182

Citations

19

References

2012

Year

M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, Dyana K. Sumner, William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny,

Clinical Cancer Research

Abstract

Temozolomide has activity in relapsed SCLC, particularly for brain metastases. Response to temozolomide may correlate with MGMT methylation in SCLC.

References

	Year	Citations

Page 1